nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosentan—ABCB11—Daunorubicin—hematologic cancer	0.096	0.164	CbGbCtD
Bosentan—ABCB11—Vinblastine—hematologic cancer	0.0408	0.0697	CbGbCtD
Bosentan—ABCB11—Vincristine—hematologic cancer	0.0401	0.0685	CbGbCtD
Bosentan—ABCB11—Dexamethasone—hematologic cancer	0.0302	0.0516	CbGbCtD
Bosentan—CYP2C9—Bexarotene—hematologic cancer	0.0289	0.0493	CbGbCtD
Bosentan—ABCB11—Doxorubicin—hematologic cancer	0.0251	0.0428	CbGbCtD
Bosentan—CYP2C9—Idarubicin—hematologic cancer	0.024	0.0409	CbGbCtD
Bosentan—CYP2C9—Bortezomib—hematologic cancer	0.0177	0.0302	CbGbCtD
Bosentan—CYP3A4—Bexarotene—hematologic cancer	0.0168	0.0287	CbGbCtD
Bosentan—CYP3A4—Busulfan—hematologic cancer	0.0156	0.0267	CbGbCtD
Bosentan—CYP3A4—Lomustine—hematologic cancer	0.0156	0.0267	CbGbCtD
Bosentan—CYP2C9—Thalidomide—hematologic cancer	0.0154	0.0263	CbGbCtD
Bosentan—CYP2C9—Teniposide—hematologic cancer	0.0147	0.0251	CbGbCtD
Bosentan—CYP3A4—Thiotepa—hematologic cancer	0.0139	0.0238	CbGbCtD
Bosentan—CYP2C9—Ifosfamide—hematologic cancer	0.0136	0.0232	CbGbCtD
Bosentan—CYP2C9—Imatinib—hematologic cancer	0.013	0.0222	CbGbCtD
Bosentan—CYP2C9—Nilotinib—hematologic cancer	0.0118	0.0201	CbGbCtD
Bosentan—CYP3A4—Methoxsalen—hematologic cancer	0.0108	0.0185	CbGbCtD
Bosentan—CYP3A4—Bortezomib—hematologic cancer	0.0103	0.0176	CbGbCtD
Bosentan—CYP3A4—Daunorubicin—hematologic cancer	0.00985	0.0168	CbGbCtD
Bosentan—CYP3A4—Cytarabine—hematologic cancer	0.00869	0.0148	CbGbCtD
Bosentan—CYP3A4—Teniposide—hematologic cancer	0.00856	0.0146	CbGbCtD
Bosentan—CYP3A4—Ifosfamide—hematologic cancer	0.0079	0.0135	CbGbCtD
Bosentan—CYP3A4—Imatinib—hematologic cancer	0.00755	0.0129	CbGbCtD
Bosentan—CYP3A4—Ruxolitinib—hematologic cancer	0.00711	0.0121	CbGbCtD
Bosentan—CYP3A4—Nilotinib—hematologic cancer	0.00686	0.0117	CbGbCtD
Bosentan—CYP3A4—Vinorelbine—hematologic cancer	0.0068	0.0116	CbGbCtD
Bosentan—CYP2C9—Cisplatin—hematologic cancer	0.00661	0.0113	CbGbCtD
Bosentan—CYP3A4—Triamcinolone—hematologic cancer	0.00622	0.0106	CbGbCtD
Bosentan—CYP3A4—Dasatinib—hematologic cancer	0.00606	0.0103	CbGbCtD
Bosentan—CYP3A4—Mitoxantrone—hematologic cancer	0.00599	0.0102	CbGbCtD
Bosentan—CYP2C9—Dexamethasone—hematologic cancer	0.00534	0.00911	CbGbCtD
Bosentan—CYP3A4—Betamethasone—hematologic cancer	0.00534	0.00911	CbGbCtD
Bosentan—CYP3A4—Prednisolone—hematologic cancer	0.00527	0.00899	CbGbCtD
Bosentan—CYP3A4—Prednisone—hematologic cancer	0.00497	0.00849	CbGbCtD
Bosentan—CYP3A4—Irinotecan—hematologic cancer	0.00472	0.00805	CbGbCtD
Bosentan—CYP3A4—Vinblastine—hematologic cancer	0.00419	0.00715	CbGbCtD
Bosentan—CYP3A4—Vincristine—hematologic cancer	0.00412	0.00703	CbGbCtD
Bosentan—CYP3A4—Etoposide—hematologic cancer	0.00378	0.00644	CbGbCtD
Bosentan—CYP3A4—Dexamethasone—hematologic cancer	0.0031	0.0053	CbGbCtD
Bosentan—CYP3A4—Doxorubicin—hematologic cancer	0.00258	0.0044	CbGbCtD
Bosentan—EDNRB—lung—hematologic cancer	0.000254	0.144	CbGeAlD
Bosentan—EDNRB—testis—hematologic cancer	0.00024	0.136	CbGeAlD
Bosentan—EDNRA—lung—hematologic cancer	0.00021	0.119	CbGeAlD
Bosentan—EDNRA—testis—hematologic cancer	0.000198	0.112	CbGeAlD
Bosentan—ABCB11—testis—hematologic cancer	0.000194	0.11	CbGeAlD
Bosentan—EDNRB—lymph node—hematologic cancer	0.000174	0.0985	CbGeAlD
Bosentan—EDNRA—lymph node—hematologic cancer	0.000144	0.0814	CbGeAlD
Bosentan—CYP2C9—hematopoietic system—hematologic cancer	0.00012	0.0678	CbGeAlD
Bosentan—CYP3A4—hematopoietic system—hematologic cancer	9.13e-05	0.0517	CbGeAlD
Bosentan—CYP2C9—blood—hematologic cancer	7.93e-05	0.0449	CbGeAlD
Bosentan—CYP3A4—blood—hematologic cancer	6.05e-05	0.0343	CbGeAlD
Bosentan—Gastrointestinal disorder—Betamethasone—hematologic cancer	2.35e-05	7.55e-05	CcSEcCtD
Bosentan—Gastrointestinal disorder—Dexamethasone—hematologic cancer	2.35e-05	7.55e-05	CcSEcCtD
Bosentan—Back pain—Methotrexate—hematologic cancer	2.34e-05	7.55e-05	CcSEcCtD
Bosentan—Fatigue—Betamethasone—hematologic cancer	2.34e-05	7.54e-05	CcSEcCtD
Bosentan—Fatigue—Dexamethasone—hematologic cancer	2.34e-05	7.54e-05	CcSEcCtD
Bosentan—Chills—Epirubicin—hematologic cancer	2.34e-05	7.53e-05	CcSEcCtD
Bosentan—Pruritus—Etoposide—hematologic cancer	2.34e-05	7.52e-05	CcSEcCtD
Bosentan—Shock—Prednisone—hematologic cancer	2.33e-05	7.5e-05	CcSEcCtD
Bosentan—Pain—Dexamethasone—hematologic cancer	2.32e-05	7.48e-05	CcSEcCtD
Bosentan—Pain—Betamethasone—hematologic cancer	2.32e-05	7.48e-05	CcSEcCtD
Bosentan—Nervous system disorder—Prednisone—hematologic cancer	2.32e-05	7.47e-05	CcSEcCtD
Bosentan—Tachycardia—Prednisone—hematologic cancer	2.31e-05	7.44e-05	CcSEcCtD
Bosentan—Skin disorder—Prednisone—hematologic cancer	2.3e-05	7.4e-05	CcSEcCtD
Bosentan—Nausea—Gemcitabine—hematologic cancer	2.3e-05	7.4e-05	CcSEcCtD
Bosentan—Vomiting—Cisplatin—hematologic cancer	2.29e-05	7.38e-05	CcSEcCtD
Bosentan—Hyperhidrosis—Prednisone—hematologic cancer	2.29e-05	7.37e-05	CcSEcCtD
Bosentan—Vision blurred—Methotrexate—hematologic cancer	2.28e-05	7.35e-05	CcSEcCtD
Bosentan—Mental disorder—Epirubicin—hematologic cancer	2.28e-05	7.35e-05	CcSEcCtD
Bosentan—Erythema multiforme—Doxorubicin—hematologic cancer	2.28e-05	7.34e-05	CcSEcCtD
Bosentan—Rash—Cisplatin—hematologic cancer	2.27e-05	7.32e-05	CcSEcCtD
Bosentan—Dermatitis—Cisplatin—hematologic cancer	2.27e-05	7.31e-05	CcSEcCtD
Bosentan—Erythema—Epirubicin—hematologic cancer	2.27e-05	7.3e-05	CcSEcCtD
Bosentan—Malnutrition—Epirubicin—hematologic cancer	2.27e-05	7.3e-05	CcSEcCtD
Bosentan—Diarrhoea—Etoposide—hematologic cancer	2.26e-05	7.28e-05	CcSEcCtD
Bosentan—Anorexia—Prednisone—hematologic cancer	2.26e-05	7.26e-05	CcSEcCtD
Bosentan—Eye disorder—Doxorubicin—hematologic cancer	2.25e-05	7.25e-05	CcSEcCtD
Bosentan—Tinnitus—Doxorubicin—hematologic cancer	2.25e-05	7.24e-05	CcSEcCtD
Bosentan—Anaemia—Methotrexate—hematologic cancer	2.24e-05	7.21e-05	CcSEcCtD
Bosentan—Flushing—Doxorubicin—hematologic cancer	2.24e-05	7.2e-05	CcSEcCtD
Bosentan—Cardiac disorder—Doxorubicin—hematologic cancer	2.24e-05	7.2e-05	CcSEcCtD
Bosentan—Flatulence—Epirubicin—hematologic cancer	2.24e-05	7.2e-05	CcSEcCtD
Bosentan—Gastrointestinal pain—Dexamethasone—hematologic cancer	2.22e-05	7.16e-05	CcSEcCtD
Bosentan—Gastrointestinal pain—Betamethasone—hematologic cancer	2.22e-05	7.16e-05	CcSEcCtD
Bosentan—Hypersensitivity—Triamcinolone—hematologic cancer	2.21e-05	7.11e-05	CcSEcCtD
Bosentan—Back pain—Epirubicin—hematologic cancer	2.19e-05	7.06e-05	CcSEcCtD
Bosentan—Angiopathy—Doxorubicin—hematologic cancer	2.19e-05	7.04e-05	CcSEcCtD
Bosentan—Dizziness—Etoposide—hematologic cancer	2.18e-05	7.03e-05	CcSEcCtD
Bosentan—Muscle spasms—Epirubicin—hematologic cancer	2.18e-05	7.02e-05	CcSEcCtD
Bosentan—Immune system disorder—Doxorubicin—hematologic cancer	2.18e-05	7.01e-05	CcSEcCtD
Bosentan—Vertigo—Methotrexate—hematologic cancer	2.18e-05	7.01e-05	CcSEcCtD
Bosentan—Mediastinal disorder—Doxorubicin—hematologic cancer	2.17e-05	7e-05	CcSEcCtD
Bosentan—Leukopenia—Methotrexate—hematologic cancer	2.17e-05	6.99e-05	CcSEcCtD
Bosentan—Chills—Doxorubicin—hematologic cancer	2.16e-05	6.97e-05	CcSEcCtD
Bosentan—Urticaria—Betamethasone—hematologic cancer	2.16e-05	6.95e-05	CcSEcCtD
Bosentan—Urticaria—Dexamethasone—hematologic cancer	2.16e-05	6.95e-05	CcSEcCtD
Bosentan—Musculoskeletal discomfort—Prednisone—hematologic cancer	2.16e-05	6.94e-05	CcSEcCtD
Bosentan—Dizziness—Prednisolone—hematologic cancer	2.15e-05	6.94e-05	CcSEcCtD
Bosentan—Asthenia—Triamcinolone—hematologic cancer	2.15e-05	6.92e-05	CcSEcCtD
Bosentan—Body temperature increased—Dexamethasone—hematologic cancer	2.15e-05	6.92e-05	CcSEcCtD
Bosentan—Abdominal pain—Betamethasone—hematologic cancer	2.15e-05	6.92e-05	CcSEcCtD
Bosentan—Abdominal pain—Dexamethasone—hematologic cancer	2.15e-05	6.92e-05	CcSEcCtD
Bosentan—Body temperature increased—Betamethasone—hematologic cancer	2.15e-05	6.92e-05	CcSEcCtD
Bosentan—Nausea—Cisplatin—hematologic cancer	2.14e-05	6.89e-05	CcSEcCtD
Bosentan—Insomnia—Prednisone—hematologic cancer	2.14e-05	6.89e-05	CcSEcCtD
Bosentan—Vision blurred—Epirubicin—hematologic cancer	2.14e-05	6.88e-05	CcSEcCtD
Bosentan—Paraesthesia—Prednisone—hematologic cancer	2.13e-05	6.84e-05	CcSEcCtD
Bosentan—Pruritus—Triamcinolone—hematologic cancer	2.12e-05	6.82e-05	CcSEcCtD
Bosentan—Cough—Methotrexate—hematologic cancer	2.12e-05	6.81e-05	CcSEcCtD
Bosentan—Mental disorder—Doxorubicin—hematologic cancer	2.11e-05	6.8e-05	CcSEcCtD
Bosentan—Vomiting—Etoposide—hematologic cancer	2.1e-05	6.76e-05	CcSEcCtD
Bosentan—Erythema—Doxorubicin—hematologic cancer	2.1e-05	6.76e-05	CcSEcCtD
Bosentan—Malnutrition—Doxorubicin—hematologic cancer	2.1e-05	6.76e-05	CcSEcCtD
Bosentan—Anaemia—Epirubicin—hematologic cancer	2.1e-05	6.75e-05	CcSEcCtD
Bosentan—Dyspepsia—Prednisone—hematologic cancer	2.08e-05	6.71e-05	CcSEcCtD
Bosentan—Rash—Etoposide—hematologic cancer	2.08e-05	6.7e-05	CcSEcCtD
Bosentan—Dermatitis—Etoposide—hematologic cancer	2.08e-05	6.7e-05	CcSEcCtD
Bosentan—Headache—Etoposide—hematologic cancer	2.07e-05	6.66e-05	CcSEcCtD
Bosentan—Flatulence—Doxorubicin—hematologic cancer	2.07e-05	6.66e-05	CcSEcCtD
Bosentan—Chest pain—Methotrexate—hematologic cancer	2.06e-05	6.64e-05	CcSEcCtD
Bosentan—Arthralgia—Methotrexate—hematologic cancer	2.06e-05	6.64e-05	CcSEcCtD
Bosentan—Decreased appetite—Prednisone—hematologic cancer	2.06e-05	6.62e-05	CcSEcCtD
Bosentan—Rash—Prednisolone—hematologic cancer	2.05e-05	6.61e-05	CcSEcCtD
Bosentan—Dermatitis—Prednisolone—hematologic cancer	2.05e-05	6.61e-05	CcSEcCtD
Bosentan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	2.05e-05	6.6e-05	CcSEcCtD
Bosentan—Fatigue—Prednisone—hematologic cancer	2.04e-05	6.57e-05	CcSEcCtD
Bosentan—Headache—Prednisolone—hematologic cancer	2.04e-05	6.57e-05	CcSEcCtD
Bosentan—Discomfort—Methotrexate—hematologic cancer	2.04e-05	6.56e-05	CcSEcCtD
Bosentan—Vertigo—Epirubicin—hematologic cancer	2.04e-05	6.56e-05	CcSEcCtD
Bosentan—Syncope—Epirubicin—hematologic cancer	2.03e-05	6.55e-05	CcSEcCtD
Bosentan—Leukopenia—Epirubicin—hematologic cancer	2.03e-05	6.54e-05	CcSEcCtD
Bosentan—Back pain—Doxorubicin—hematologic cancer	2.03e-05	6.54e-05	CcSEcCtD
Bosentan—Constipation—Prednisone—hematologic cancer	2.02e-05	6.52e-05	CcSEcCtD
Bosentan—Muscle spasms—Doxorubicin—hematologic cancer	2.02e-05	6.5e-05	CcSEcCtD
Bosentan—Palpitations—Epirubicin—hematologic cancer	2e-05	6.45e-05	CcSEcCtD
Bosentan—Loss of consciousness—Epirubicin—hematologic cancer	1.99e-05	6.42e-05	CcSEcCtD
Bosentan—Dizziness—Triamcinolone—hematologic cancer	1.98e-05	6.38e-05	CcSEcCtD
Bosentan—Cough—Epirubicin—hematologic cancer	1.98e-05	6.37e-05	CcSEcCtD
Bosentan—Anaphylactic shock—Methotrexate—hematologic cancer	1.98e-05	6.37e-05	CcSEcCtD
Bosentan—Vision blurred—Doxorubicin—hematologic cancer	1.98e-05	6.37e-05	CcSEcCtD
Bosentan—Infection—Methotrexate—hematologic cancer	1.97e-05	6.33e-05	CcSEcCtD
Bosentan—Nausea—Etoposide—hematologic cancer	1.96e-05	6.32e-05	CcSEcCtD
Bosentan—Asthenia—Betamethasone—hematologic cancer	1.95e-05	6.28e-05	CcSEcCtD
Bosentan—Asthenia—Dexamethasone—hematologic cancer	1.95e-05	6.28e-05	CcSEcCtD
Bosentan—Nervous system disorder—Methotrexate—hematologic cancer	1.94e-05	6.25e-05	CcSEcCtD
Bosentan—Anaemia—Doxorubicin—hematologic cancer	1.94e-05	6.25e-05	CcSEcCtD
Bosentan—Thrombocytopenia—Methotrexate—hematologic cancer	1.94e-05	6.24e-05	CcSEcCtD
Bosentan—Gastrointestinal pain—Prednisone—hematologic cancer	1.94e-05	6.23e-05	CcSEcCtD
Bosentan—Nausea—Prednisolone—hematologic cancer	1.94e-05	6.23e-05	CcSEcCtD
Bosentan—Chest pain—Epirubicin—hematologic cancer	1.93e-05	6.22e-05	CcSEcCtD
Bosentan—Arthralgia—Epirubicin—hematologic cancer	1.93e-05	6.22e-05	CcSEcCtD
Bosentan—Anxiety—Epirubicin—hematologic cancer	1.92e-05	6.2e-05	CcSEcCtD
Bosentan—Pruritus—Betamethasone—hematologic cancer	1.92e-05	6.19e-05	CcSEcCtD
Bosentan—Pruritus—Dexamethasone—hematologic cancer	1.92e-05	6.19e-05	CcSEcCtD
Bosentan—Skin disorder—Methotrexate—hematologic cancer	1.92e-05	6.19e-05	CcSEcCtD
Bosentan—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	1.92e-05	6.17e-05	CcSEcCtD
Bosentan—Hyperhidrosis—Methotrexate—hematologic cancer	1.91e-05	6.16e-05	CcSEcCtD
Bosentan—Discomfort—Epirubicin—hematologic cancer	1.91e-05	6.14e-05	CcSEcCtD
Bosentan—Vomiting—Triamcinolone—hematologic cancer	1.9e-05	6.13e-05	CcSEcCtD
Bosentan—Rash—Triamcinolone—hematologic cancer	1.89e-05	6.08e-05	CcSEcCtD
Bosentan—Dry mouth—Epirubicin—hematologic cancer	1.89e-05	6.08e-05	CcSEcCtD
Bosentan—Dermatitis—Triamcinolone—hematologic cancer	1.89e-05	6.08e-05	CcSEcCtD
Bosentan—Vertigo—Doxorubicin—hematologic cancer	1.89e-05	6.07e-05	CcSEcCtD
Bosentan—Anorexia—Methotrexate—hematologic cancer	1.89e-05	6.07e-05	CcSEcCtD
Bosentan—Syncope—Doxorubicin—hematologic cancer	1.88e-05	6.06e-05	CcSEcCtD
Bosentan—Urticaria—Prednisone—hematologic cancer	1.88e-05	6.05e-05	CcSEcCtD
Bosentan—Leukopenia—Doxorubicin—hematologic cancer	1.88e-05	6.05e-05	CcSEcCtD
Bosentan—Headache—Triamcinolone—hematologic cancer	1.88e-05	6.04e-05	CcSEcCtD
Bosentan—Abdominal pain—Prednisone—hematologic cancer	1.87e-05	6.02e-05	CcSEcCtD
Bosentan—Body temperature increased—Prednisone—hematologic cancer	1.87e-05	6.02e-05	CcSEcCtD
Bosentan—Diarrhoea—Betamethasone—hematologic cancer	1.86e-05	5.99e-05	CcSEcCtD
Bosentan—Diarrhoea—Dexamethasone—hematologic cancer	1.86e-05	5.99e-05	CcSEcCtD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—NCOA3—hematologic cancer	1.86e-05	0.000183	CbGpPWpGaD
Bosentan—Palpitations—Doxorubicin—hematologic cancer	1.86e-05	5.97e-05	CcSEcCtD
Bosentan—CYP3A4—Metapathway biotransformation—GSTM1—hematologic cancer	1.85e-05	0.000182	CbGpPWpGaD
Bosentan—Anaphylactic shock—Epirubicin—hematologic cancer	1.85e-05	5.96e-05	CcSEcCtD
Bosentan—Oedema—Epirubicin—hematologic cancer	1.85e-05	5.96e-05	CcSEcCtD
Bosentan—Hypotension—Methotrexate—hematologic cancer	1.85e-05	5.95e-05	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—BRAF—hematologic cancer	1.85e-05	0.000182	CbGpPWpGaD
Bosentan—Loss of consciousness—Doxorubicin—hematologic cancer	1.84e-05	5.94e-05	CcSEcCtD
Bosentan—EDNRA—Signaling Pathways—FOXO1—hematologic cancer	1.84e-05	0.000182	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—IL2—hematologic cancer	1.84e-05	0.000181	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—PDGFRB—hematologic cancer	1.84e-05	0.000181	CbGpPWpGaD
Bosentan—Infection—Epirubicin—hematologic cancer	1.84e-05	5.92e-05	CcSEcCtD
Bosentan—Cough—Doxorubicin—hematologic cancer	1.83e-05	5.9e-05	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—CCL2—hematologic cancer	1.83e-05	0.00018	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—IL6R—hematologic cancer	1.82e-05	0.00018	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—PIK3CB—hematologic cancer	1.82e-05	0.000179	CbGpPWpGaD
Bosentan—Shock—Epirubicin—hematologic cancer	1.82e-05	5.86e-05	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—CREBBP—hematologic cancer	1.82e-05	0.000179	CbGpPWpGaD
Bosentan—Nervous system disorder—Epirubicin—hematologic cancer	1.82e-05	5.85e-05	CcSEcCtD
Bosentan—Thrombocytopenia—Epirubicin—hematologic cancer	1.81e-05	5.84e-05	CcSEcCtD
Bosentan—EDNRA—Signaling Pathways—PDGFRA—hematologic cancer	1.81e-05	0.000178	CbGpPWpGaD
Bosentan—Tachycardia—Epirubicin—hematologic cancer	1.81e-05	5.82e-05	CcSEcCtD
Bosentan—EDNRA—Signaling Pathways—JAK1—hematologic cancer	1.81e-05	0.000178	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—PRKCG—hematologic cancer	1.81e-05	0.000178	CbGpPWpGaD
Bosentan—Musculoskeletal discomfort—Methotrexate—hematologic cancer	1.8e-05	5.8e-05	CcSEcCtD
Bosentan—ABCB11—Metabolism—CYCS—hematologic cancer	1.8e-05	0.000177	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—HDC—hematologic cancer	1.8e-05	0.000177	CbGpPWpGaD
Bosentan—Skin disorder—Epirubicin—hematologic cancer	1.8e-05	5.79e-05	CcSEcCtD
Bosentan—Dizziness—Dexamethasone—hematologic cancer	1.8e-05	5.79e-05	CcSEcCtD
Bosentan—Dizziness—Betamethasone—hematologic cancer	1.8e-05	5.79e-05	CcSEcCtD
Bosentan—Hyperhidrosis—Epirubicin—hematologic cancer	1.79e-05	5.76e-05	CcSEcCtD
Bosentan—Insomnia—Methotrexate—hematologic cancer	1.79e-05	5.76e-05	CcSEcCtD
Bosentan—ABCB11—Metabolism—HSP90AA1—hematologic cancer	1.79e-05	0.000176	CbGpPWpGaD
Bosentan—Chest pain—Doxorubicin—hematologic cancer	1.79e-05	5.75e-05	CcSEcCtD
Bosentan—Arthralgia—Doxorubicin—hematologic cancer	1.79e-05	5.75e-05	CcSEcCtD
Bosentan—Anxiety—Doxorubicin—hematologic cancer	1.78e-05	5.73e-05	CcSEcCtD
Bosentan—Nausea—Triamcinolone—hematologic cancer	1.78e-05	5.73e-05	CcSEcCtD
Bosentan—Paraesthesia—Methotrexate—hematologic cancer	1.78e-05	5.72e-05	CcSEcCtD
Bosentan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	1.77e-05	5.71e-05	CcSEcCtD
Bosentan—Discomfort—Doxorubicin—hematologic cancer	1.77e-05	5.68e-05	CcSEcCtD
Bosentan—Anorexia—Epirubicin—hematologic cancer	1.76e-05	5.68e-05	CcSEcCtD
Bosentan—Dyspnoea—Methotrexate—hematologic cancer	1.76e-05	5.68e-05	CcSEcCtD
Bosentan—Somnolence—Methotrexate—hematologic cancer	1.76e-05	5.66e-05	CcSEcCtD
Bosentan—Dry mouth—Doxorubicin—hematologic cancer	1.75e-05	5.63e-05	CcSEcCtD
Bosentan—Hypersensitivity—Prednisone—hematologic cancer	1.74e-05	5.61e-05	CcSEcCtD
Bosentan—Dyspepsia—Methotrexate—hematologic cancer	1.74e-05	5.61e-05	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—MAP2K1—hematologic cancer	1.74e-05	0.000171	CbGpPWpGaD
Bosentan—Hypotension—Epirubicin—hematologic cancer	1.73e-05	5.57e-05	CcSEcCtD
Bosentan—Vomiting—Betamethasone—hematologic cancer	1.73e-05	5.56e-05	CcSEcCtD
Bosentan—Vomiting—Dexamethasone—hematologic cancer	1.73e-05	5.56e-05	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—PIK3CD—hematologic cancer	1.73e-05	0.00017	CbGpPWpGaD
Bosentan—Decreased appetite—Methotrexate—hematologic cancer	1.72e-05	5.54e-05	CcSEcCtD
Bosentan—Rash—Betamethasone—hematologic cancer	1.71e-05	5.52e-05	CcSEcCtD
Bosentan—Rash—Dexamethasone—hematologic cancer	1.71e-05	5.52e-05	CcSEcCtD
Bosentan—Anaphylactic shock—Doxorubicin—hematologic cancer	1.71e-05	5.51e-05	CcSEcCtD
Bosentan—Oedema—Doxorubicin—hematologic cancer	1.71e-05	5.51e-05	CcSEcCtD
Bosentan—Dermatitis—Betamethasone—hematologic cancer	1.71e-05	5.51e-05	CcSEcCtD
Bosentan—Dermatitis—Dexamethasone—hematologic cancer	1.71e-05	5.51e-05	CcSEcCtD
Bosentan—EDNRB—GPCR downstream signaling—PIK3CA—hematologic cancer	1.71e-05	0.000168	CbGpPWpGaD
Bosentan—Gastrointestinal disorder—Methotrexate—hematologic cancer	1.71e-05	5.5e-05	CcSEcCtD
Bosentan—Fatigue—Methotrexate—hematologic cancer	1.71e-05	5.49e-05	CcSEcCtD
Bosentan—Headache—Betamethasone—hematologic cancer	1.7e-05	5.48e-05	CcSEcCtD
Bosentan—Headache—Dexamethasone—hematologic cancer	1.7e-05	5.48e-05	CcSEcCtD
Bosentan—Infection—Doxorubicin—hematologic cancer	1.7e-05	5.48e-05	CcSEcCtD
Bosentan—Asthenia—Prednisone—hematologic cancer	1.7e-05	5.47e-05	CcSEcCtD
Bosentan—Pain—Methotrexate—hematologic cancer	1.69e-05	5.45e-05	CcSEcCtD
Bosentan—EDNRB—Signaling by GPCR—KRAS—hematologic cancer	1.69e-05	0.000166	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—IL2RA—hematologic cancer	1.69e-05	0.000166	CbGpPWpGaD
Bosentan—Musculoskeletal discomfort—Epirubicin—hematologic cancer	1.69e-05	5.43e-05	CcSEcCtD
Bosentan—Shock—Doxorubicin—hematologic cancer	1.69e-05	5.43e-05	CcSEcCtD
Bosentan—Nervous system disorder—Doxorubicin—hematologic cancer	1.68e-05	5.41e-05	CcSEcCtD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—SDC1—hematologic cancer	1.68e-05	0.000165	CbGpPWpGaD
Bosentan—Thrombocytopenia—Doxorubicin—hematologic cancer	1.68e-05	5.4e-05	CcSEcCtD
Bosentan—Pruritus—Prednisone—hematologic cancer	1.67e-05	5.39e-05	CcSEcCtD
Bosentan—Insomnia—Epirubicin—hematologic cancer	1.67e-05	5.39e-05	CcSEcCtD
Bosentan—EDNRA—Signaling by GPCR—IL2—hematologic cancer	1.67e-05	0.000165	CbGpPWpGaD
Bosentan—Tachycardia—Doxorubicin—hematologic cancer	1.67e-05	5.38e-05	CcSEcCtD
Bosentan—EDNRA—Signaling Pathways—TERT—hematologic cancer	1.67e-05	0.000164	CbGpPWpGaD
Bosentan—Skin disorder—Doxorubicin—hematologic cancer	1.66e-05	5.36e-05	CcSEcCtD
Bosentan—Paraesthesia—Epirubicin—hematologic cancer	1.66e-05	5.35e-05	CcSEcCtD
Bosentan—Hyperhidrosis—Doxorubicin—hematologic cancer	1.66e-05	5.33e-05	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—FGF2—hematologic cancer	1.65e-05	0.000163	CbGpPWpGaD
Bosentan—Dyspnoea—Epirubicin—hematologic cancer	1.65e-05	5.31e-05	CcSEcCtD
Bosentan—CYP2C9—Metabolism—CDA—hematologic cancer	1.65e-05	0.000162	CbGpPWpGaD
Bosentan—Somnolence—Epirubicin—hematologic cancer	1.65e-05	5.3e-05	CcSEcCtD
Bosentan—Anorexia—Doxorubicin—hematologic cancer	1.63e-05	5.26e-05	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—PIK3R1—hematologic cancer	1.63e-05	0.00016	CbGpPWpGaD
Bosentan—Dyspepsia—Epirubicin—hematologic cancer	1.63e-05	5.25e-05	CcSEcCtD
Bosentan—EDNRA—Signaling Pathways—PDGFB—hematologic cancer	1.63e-05	0.00016	CbGpPWpGaD
Bosentan—Diarrhoea—Prednisone—hematologic cancer	1.62e-05	5.21e-05	CcSEcCtD
Bosentan—Gastrointestinal pain—Methotrexate—hematologic cancer	1.62e-05	5.21e-05	CcSEcCtD
Bosentan—Nausea—Dexamethasone—hematologic cancer	1.61e-05	5.2e-05	CcSEcCtD
Bosentan—Nausea—Betamethasone—hematologic cancer	1.61e-05	5.2e-05	CcSEcCtD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	1.61e-05	0.000159	CbGpPWpGaD
Bosentan—Decreased appetite—Epirubicin—hematologic cancer	1.61e-05	5.18e-05	CcSEcCtD
Bosentan—Hypotension—Doxorubicin—hematologic cancer	1.6e-05	5.15e-05	CcSEcCtD
Bosentan—Gastrointestinal disorder—Epirubicin—hematologic cancer	1.6e-05	5.15e-05	CcSEcCtD
Bosentan—Fatigue—Epirubicin—hematologic cancer	1.6e-05	5.14e-05	CcSEcCtD
Bosentan—EDNRA—Signaling Pathways—TSC2—hematologic cancer	1.59e-05	0.000157	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—GSTP1—hematologic cancer	1.59e-05	0.000156	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PC—hematologic cancer	1.58e-05	0.000156	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—JAK2—hematologic cancer	1.58e-05	0.000156	CbGpPWpGaD
Bosentan—Pain—Epirubicin—hematologic cancer	1.58e-05	5.1e-05	CcSEcCtD
Bosentan—Constipation—Epirubicin—hematologic cancer	1.58e-05	5.1e-05	CcSEcCtD
Bosentan—Urticaria—Methotrexate—hematologic cancer	1.57e-05	5.06e-05	CcSEcCtD
Bosentan—CYP3A4—Metabolism—PHYH—hematologic cancer	1.57e-05	0.000154	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—FTCD—hematologic cancer	1.57e-05	0.000154	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—GMPS—hematologic cancer	1.57e-05	0.000154	CbGpPWpGaD
Bosentan—Dizziness—Prednisone—hematologic cancer	1.57e-05	5.04e-05	CcSEcCtD
Bosentan—Abdominal pain—Methotrexate—hematologic cancer	1.56e-05	5.03e-05	CcSEcCtD
Bosentan—Body temperature increased—Methotrexate—hematologic cancer	1.56e-05	5.03e-05	CcSEcCtD
Bosentan—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	1.56e-05	5.02e-05	CcSEcCtD
Bosentan—EDNRB—Signaling by GPCR—PIK3CA—hematologic cancer	1.55e-05	0.000153	CbGpPWpGaD
Bosentan—Insomnia—Doxorubicin—hematologic cancer	1.55e-05	4.99e-05	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—MDM2—hematologic cancer	1.55e-05	0.000152	CbGpPWpGaD
Bosentan—Paraesthesia—Doxorubicin—hematologic cancer	1.54e-05	4.95e-05	CcSEcCtD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	1.54e-05	0.000151	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—FGFR3—hematologic cancer	1.53e-05	0.000151	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—SLC35B2—hematologic cancer	1.53e-05	0.000151	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—GBA—hematologic cancer	1.53e-05	0.000151	CbGpPWpGaD
Bosentan—Dyspnoea—Doxorubicin—hematologic cancer	1.53e-05	4.92e-05	CcSEcCtD
Bosentan—Somnolence—Doxorubicin—hematologic cancer	1.52e-05	4.9e-05	CcSEcCtD
Bosentan—EDNRA—Signaling Pathways—MAPK14—hematologic cancer	1.52e-05	0.000149	CbGpPWpGaD
Bosentan—Gastrointestinal pain—Epirubicin—hematologic cancer	1.51e-05	4.87e-05	CcSEcCtD
Bosentan—Dyspepsia—Doxorubicin—hematologic cancer	1.51e-05	4.85e-05	CcSEcCtD
Bosentan—Vomiting—Prednisone—hematologic cancer	1.51e-05	4.85e-05	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—MTOR—hematologic cancer	1.5e-05	0.000148	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—PIK3CB—hematologic cancer	1.5e-05	0.000148	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—ABCB1—hematologic cancer	1.5e-05	0.000148	CbGpPWpGaD
Bosentan—Rash—Prednisone—hematologic cancer	1.49e-05	4.81e-05	CcSEcCtD
Bosentan—Dermatitis—Prednisone—hematologic cancer	1.49e-05	4.8e-05	CcSEcCtD
Bosentan—Decreased appetite—Doxorubicin—hematologic cancer	1.49e-05	4.79e-05	CcSEcCtD
Bosentan—EDNRA—Signaling Pathways—ESR1—hematologic cancer	1.49e-05	0.000146	CbGpPWpGaD
Bosentan—Headache—Prednisone—hematologic cancer	1.48e-05	4.77e-05	CcSEcCtD
Bosentan—Gastrointestinal disorder—Doxorubicin—hematologic cancer	1.48e-05	4.76e-05	CcSEcCtD
Bosentan—Fatigue—Doxorubicin—hematologic cancer	1.48e-05	4.75e-05	CcSEcCtD
Bosentan—Urticaria—Epirubicin—hematologic cancer	1.47e-05	4.73e-05	CcSEcCtD
Bosentan—EDNRA—Signaling Pathways—FN1—hematologic cancer	1.47e-05	0.000145	CbGpPWpGaD
Bosentan—Pain—Doxorubicin—hematologic cancer	1.46e-05	4.72e-05	CcSEcCtD
Bosentan—Constipation—Doxorubicin—hematologic cancer	1.46e-05	4.72e-05	CcSEcCtD
Bosentan—Abdominal pain—Epirubicin—hematologic cancer	1.46e-05	4.71e-05	CcSEcCtD
Bosentan—Body temperature increased—Epirubicin—hematologic cancer	1.46e-05	4.71e-05	CcSEcCtD
Bosentan—ABCB11—Metabolism—NCOR1—hematologic cancer	1.46e-05	0.000144	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—GSTM1—hematologic cancer	1.46e-05	0.000144	CbGpPWpGaD
Bosentan—Hypersensitivity—Methotrexate—hematologic cancer	1.46e-05	4.69e-05	CcSEcCtD
Bosentan—EDNRA—Signaling Pathways—BAD—hematologic cancer	1.45e-05	0.000143	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—NFKBIA—hematologic cancer	1.45e-05	0.000143	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—NOTCH1—hematologic cancer	1.44e-05	0.000141	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—HRAS—hematologic cancer	1.44e-05	0.000141	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—SMPD3—hematologic cancer	1.43e-05	0.000141	CbGpPWpGaD
Bosentan—Asthenia—Methotrexate—hematologic cancer	1.42e-05	4.57e-05	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—CDKN1B—hematologic cancer	1.41e-05	0.000139	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—CD80—hematologic cancer	1.41e-05	0.000139	CbGpPWpGaD
Bosentan—Nausea—Prednisone—hematologic cancer	1.41e-05	4.53e-05	CcSEcCtD
Bosentan—EDNRA—Signaling Pathways—KIT—hematologic cancer	1.41e-05	0.000138	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—PIK3CG—hematologic cancer	1.41e-05	0.000138	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—NRAS—hematologic cancer	1.41e-05	0.000138	CbGpPWpGaD
Bosentan—Gastrointestinal pain—Doxorubicin—hematologic cancer	1.4e-05	4.51e-05	CcSEcCtD
Bosentan—Pruritus—Methotrexate—hematologic cancer	1.4e-05	4.51e-05	CcSEcCtD
Bosentan—CYP2C9—Metabolism—MTAP—hematologic cancer	1.4e-05	0.000138	CbGpPWpGaD
Bosentan—EDNRB—GPCR downstream signaling—AKT1—hematologic cancer	1.4e-05	0.000138	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—CASP3—hematologic cancer	1.38e-05	0.000136	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—IL2—hematologic cancer	1.38e-05	0.000136	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—PTPN11—hematologic cancer	1.38e-05	0.000136	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—IL6—hematologic cancer	1.38e-05	0.000135	CbGpPWpGaD
Bosentan—Hypersensitivity—Epirubicin—hematologic cancer	1.36e-05	4.39e-05	CcSEcCtD
Bosentan—Urticaria—Doxorubicin—hematologic cancer	1.36e-05	4.38e-05	CcSEcCtD
Bosentan—Body temperature increased—Doxorubicin—hematologic cancer	1.35e-05	4.36e-05	CcSEcCtD
Bosentan—Abdominal pain—Doxorubicin—hematologic cancer	1.35e-05	4.36e-05	CcSEcCtD
Bosentan—Diarrhoea—Methotrexate—hematologic cancer	1.35e-05	4.36e-05	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—CCND1—hematologic cancer	1.35e-05	0.000133	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—MAPK3—hematologic cancer	1.35e-05	0.000133	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—JUN—hematologic cancer	1.34e-05	0.000132	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—CREB1—hematologic cancer	1.34e-05	0.000132	CbGpPWpGaD
Bosentan—Asthenia—Epirubicin—hematologic cancer	1.33e-05	4.28e-05	CcSEcCtD
Bosentan—EDNRA—Signaling Pathways—BRAF—hematologic cancer	1.32e-05	0.00013	CbGpPWpGaD
Bosentan—Pruritus—Epirubicin—hematologic cancer	1.31e-05	4.22e-05	CcSEcCtD
Bosentan—EDNRA—Signaling Pathways—CCL2—hematologic cancer	1.31e-05	0.000129	CbGpPWpGaD
Bosentan—Dizziness—Methotrexate—hematologic cancer	1.31e-05	4.21e-05	CcSEcCtD
Bosentan—EDNRA—Signaling Pathways—IL6R—hematologic cancer	1.31e-05	0.000128	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—CDKN1A—hematologic cancer	1.3e-05	0.000128	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—CREBBP—hematologic cancer	1.3e-05	0.000128	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—PTEN—hematologic cancer	1.3e-05	0.000128	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—MTHFR—hematologic cancer	1.29e-05	0.000127	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—MAPK8—hematologic cancer	1.27e-05	0.000125	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—AKT1—hematologic cancer	1.27e-05	0.000125	CbGpPWpGaD
Bosentan—Diarrhoea—Epirubicin—hematologic cancer	1.27e-05	4.08e-05	CcSEcCtD
Bosentan—Hypersensitivity—Doxorubicin—hematologic cancer	1.26e-05	4.06e-05	CcSEcCtD
Bosentan—Vomiting—Methotrexate—hematologic cancer	1.26e-05	4.05e-05	CcSEcCtD
Bosentan—CYP3A4—Metabolism—B3GAT1—hematologic cancer	1.25e-05	0.000123	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—ASNS—hematologic cancer	1.25e-05	0.000123	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—DCK—hematologic cancer	1.25e-05	0.000123	CbGpPWpGaD
Bosentan—Rash—Methotrexate—hematologic cancer	1.25e-05	4.02e-05	CcSEcCtD
Bosentan—CYP2C9—Metabolism—FHL2—hematologic cancer	1.25e-05	0.000123	CbGpPWpGaD
Bosentan—Dermatitis—Methotrexate—hematologic cancer	1.25e-05	4.01e-05	CcSEcCtD
Bosentan—EDNRA—Signaling Pathways—MAP2K1—hematologic cancer	1.24e-05	0.000122	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—EP300—hematologic cancer	1.24e-05	0.000122	CbGpPWpGaD
Bosentan—Headache—Methotrexate—hematologic cancer	1.24e-05	3.99e-05	CcSEcCtD
Bosentan—EDNRA—Signaling Pathways—PIK3CD—hematologic cancer	1.24e-05	0.000122	CbGpPWpGaD
Bosentan—Asthenia—Doxorubicin—hematologic cancer	1.23e-05	3.96e-05	CcSEcCtD
Bosentan—Dizziness—Epirubicin—hematologic cancer	1.22e-05	3.94e-05	CcSEcCtD
Bosentan—EDNRA—GPCR downstream signaling—PIK3CA—hematologic cancer	1.22e-05	0.00012	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—AGRN—hematologic cancer	1.22e-05	0.00012	CbGpPWpGaD
Bosentan—Pruritus—Doxorubicin—hematologic cancer	1.21e-05	3.9e-05	CcSEcCtD
Bosentan—EDNRA—Signaling by GPCR—KRAS—hematologic cancer	1.21e-05	0.000119	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—SRC—hematologic cancer	1.21e-05	0.000119	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—HDC—hematologic cancer	1.19e-05	0.000117	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—FGF2—hematologic cancer	1.18e-05	0.000116	CbGpPWpGaD
Bosentan—Vomiting—Epirubicin—hematologic cancer	1.18e-05	3.79e-05	CcSEcCtD
Bosentan—Nausea—Methotrexate—hematologic cancer	1.18e-05	3.78e-05	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—VEGFA—hematologic cancer	1.17e-05	0.000116	CbGpPWpGaD
Bosentan—Diarrhoea—Doxorubicin—hematologic cancer	1.17e-05	3.77e-05	CcSEcCtD
Bosentan—Rash—Epirubicin—hematologic cancer	1.17e-05	3.76e-05	CcSEcCtD
Bosentan—EDNRA—Signaling Pathways—PIK3R1—hematologic cancer	1.17e-05	0.000115	CbGpPWpGaD
Bosentan—Dermatitis—Epirubicin—hematologic cancer	1.17e-05	3.75e-05	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—STAT3—hematologic cancer	1.16e-05	0.000114	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—NRAS—hematologic cancer	1.16e-05	0.000114	CbGpPWpGaD
Bosentan—Headache—Epirubicin—hematologic cancer	1.16e-05	3.73e-05	CcSEcCtD
Bosentan—CYP2C9—Metabolism—HMMR—hematologic cancer	1.16e-05	0.000114	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—IDH2—hematologic cancer	1.16e-05	0.000114	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.14e-05	0.000112	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—JAK2—hematologic cancer	1.13e-05	0.000112	CbGpPWpGaD
Bosentan—Dizziness—Doxorubicin—hematologic cancer	1.13e-05	3.65e-05	CcSEcCtD
Bosentan—EDNRA—Signaling by GPCR—PIK3CA—hematologic cancer	1.11e-05	0.000109	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—MAPK3—hematologic cancer	1.11e-05	0.000109	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—MDM2—hematologic cancer	1.11e-05	0.000109	CbGpPWpGaD
Bosentan—Nausea—Epirubicin—hematologic cancer	1.1e-05	3.54e-05	CcSEcCtD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—hematologic cancer	1.09e-05	0.000108	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—ARNTL—hematologic cancer	1.09e-05	0.000107	CbGpPWpGaD
Bosentan—Vomiting—Doxorubicin—hematologic cancer	1.09e-05	3.51e-05	CcSEcCtD
Bosentan—CYP3A4—Metabolism—CDA—hematologic cancer	1.09e-05	0.000107	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—PIK3CG—hematologic cancer	1.08e-05	0.000107	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—MYC—hematologic cancer	1.08e-05	0.000106	CbGpPWpGaD
Bosentan—Rash—Doxorubicin—hematologic cancer	1.08e-05	3.48e-05	CcSEcCtD
Bosentan—Dermatitis—Doxorubicin—hematologic cancer	1.08e-05	3.47e-05	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—TGFB1—hematologic cancer	1.08e-05	0.000106	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—PIK3CB—hematologic cancer	1.08e-05	0.000106	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—MTOR—hematologic cancer	1.08e-05	0.000106	CbGpPWpGaD
Bosentan—Headache—Doxorubicin—hematologic cancer	1.07e-05	3.45e-05	CcSEcCtD
Bosentan—CYP2C9—Metabolism—ACP5—hematologic cancer	1.06e-05	0.000104	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—CA9—hematologic cancer	1.06e-05	0.000104	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—NCOR2—hematologic cancer	1.05e-05	0.000103	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PC—hematologic cancer	1.04e-05	0.000103	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—HRAS—hematologic cancer	1.03e-05	0.000101	CbGpPWpGaD
Bosentan—Nausea—Doxorubicin—hematologic cancer	1.02e-05	3.28e-05	CcSEcCtD
Bosentan—EDNRA—Signaling Pathways—CDKN1B—hematologic cancer	1.01e-05	9.95e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—GBA—hematologic cancer	1.01e-05	9.93e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—SLC35B2—hematologic cancer	1.01e-05	9.93e-05	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—CREBBP—hematologic cancer	1e-05	9.89e-05	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—AKT1—hematologic cancer	1e-05	9.84e-05	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—KRAS—hematologic cancer	9.98e-06	9.83e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—IDH1—hematologic cancer	9.97e-06	9.82e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—CASP3—hematologic cancer	9.91e-06	9.75e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—IL2—hematologic cancer	9.89e-06	9.74e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—GSTO1—hematologic cancer	9.86e-06	9.71e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—ABCC3—hematologic cancer	9.86e-06	9.71e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—TXN—hematologic cancer	9.86e-06	9.71e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—IL6—hematologic cancer	9.84e-06	9.69e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—SPHK1—hematologic cancer	9.65e-06	9.5e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—CCND1—hematologic cancer	9.64e-06	9.49e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—JUN—hematologic cancer	9.62e-06	9.47e-05	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—PIK3CD—hematologic cancer	9.52e-06	9.37e-05	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—ALB—hematologic cancer	9.4e-06	9.25e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—CDKN1A—hematologic cancer	9.33e-06	9.18e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—PTEN—hematologic cancer	9.31e-06	9.16e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—UGT1A1—hematologic cancer	9.27e-06	9.13e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—MTAP—hematologic cancer	9.23e-06	9.09e-05	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—PIK3CA—hematologic cancer	9.17e-06	9.03e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—MAPK8—hematologic cancer	9.1e-06	8.96e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—AKT1—hematologic cancer	9.08e-06	8.94e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—SLC22A1—hematologic cancer	9.02e-06	8.88e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—CRABP1—hematologic cancer	9.02e-06	8.88e-05	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—PIK3R1—hematologic cancer	8.99e-06	8.85e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—EP300—hematologic cancer	8.87e-06	8.74e-05	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—TP53—hematologic cancer	8.87e-06	8.74e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—ALOX5—hematologic cancer	8.79e-06	8.65e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—SRC—hematologic cancer	8.63e-06	8.5e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—NUP98—hematologic cancer	8.51e-06	8.38e-05	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—HRAS—hematologic cancer	8.49e-06	8.35e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—VEGFA—hematologic cancer	8.41e-06	8.27e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—STAT3—hematologic cancer	8.32e-06	8.19e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—NRAS—hematologic cancer	8.3e-06	8.17e-05	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—PIK3CB—hematologic cancer	8.3e-06	8.17e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—ADCY7—hematologic cancer	8.26e-06	8.13e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—NCOA3—hematologic cancer	8.26e-06	8.13e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—FHL2—hematologic cancer	8.23e-06	8.1e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—NUP214—hematologic cancer	8.21e-06	8.08e-05	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—IL6—hematologic cancer	8.12e-06	8e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	8.12e-06	7.99e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—AGRN—hematologic cancer	8.07e-06	7.94e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—MTR—hematologic cancer	8.04e-06	7.91e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—ABCG2—hematologic cancer	8.04e-06	7.91e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—MAPK3—hematologic cancer	7.95e-06	7.83e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—ENO2—hematologic cancer	7.88e-06	7.76e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—MYC—hematologic cancer	7.73e-06	7.61e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—TGFB1—hematologic cancer	7.71e-06	7.59e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—IDH2—hematologic cancer	7.65e-06	7.53e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—HMMR—hematologic cancer	7.65e-06	7.53e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—GSTT1—hematologic cancer	7.65e-06	7.53e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	7.53e-06	7.41e-05	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—AKT1—hematologic cancer	7.49e-06	7.38e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—SDC1—hematologic cancer	7.47e-06	7.36e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—ARNTL—hematologic cancer	7.19e-06	7.08e-05	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—PTEN—hematologic cancer	7.17e-06	7.06e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—KRAS—hematologic cancer	7.15e-06	7.03e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	7.14e-06	7.03e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	7.05e-06	6.94e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—ACP5—hematologic cancer	7e-06	6.89e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—CA9—hematologic cancer	7e-06	6.89e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—NCOR2—hematologic cancer	6.9e-06	6.8e-05	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—EP300—hematologic cancer	6.84e-06	6.73e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	6.74e-06	6.64e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—IDH1—hematologic cancer	6.58e-06	6.47e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—PIK3CA—hematologic cancer	6.57e-06	6.46e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—GSTO1—hematologic cancer	6.5e-06	6.4e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—TXN—hematologic cancer	6.5e-06	6.4e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—ABCC3—hematologic cancer	6.5e-06	6.4e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—SPHK1—hematologic cancer	6.36e-06	6.26e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—CD44—hematologic cancer	6.35e-06	6.26e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—NQO1—hematologic cancer	6.35e-06	6.26e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—TP53—hematologic cancer	6.35e-06	6.25e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	6.22e-06	6.13e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—UGT1A1—hematologic cancer	6.11e-06	6.02e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—HRAS—hematologic cancer	6.07e-06	5.98e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—CYCS—hematologic cancer	6.01e-06	5.92e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—HSP90AA1—hematologic cancer	5.97e-06	5.88e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—CRABP1—hematologic cancer	5.95e-06	5.86e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—SLC22A1—hematologic cancer	5.95e-06	5.86e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—IL6—hematologic cancer	5.81e-06	5.72e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—ALOX5—hematologic cancer	5.8e-06	5.71e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—NUP98—hematologic cancer	5.61e-06	5.53e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—NCOA3—hematologic cancer	5.45e-06	5.36e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—ADCY7—hematologic cancer	5.45e-06	5.36e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—NUP214—hematologic cancer	5.41e-06	5.33e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	5.38e-06	5.29e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—AKT1—hematologic cancer	5.36e-06	5.28e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—ABCG2—hematologic cancer	5.3e-06	5.22e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—MTR—hematologic cancer	5.3e-06	5.22e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—GSTP1—hematologic cancer	5.3e-06	5.22e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—ENO2—hematologic cancer	5.2e-06	5.12e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	5.13e-06	5.05e-05	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—PIK3CA—hematologic cancer	5.06e-06	4.98e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—GSTT1—hematologic cancer	5.04e-06	4.96e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—ABCB1—hematologic cancer	5.02e-06	4.94e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—SDC1—hematologic cancer	4.93e-06	4.85e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—NCOR1—hematologic cancer	4.87e-06	4.79e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—GSTM1—hematologic cancer	4.87e-06	4.79e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—MTHFR—hematologic cancer	4.3e-06	4.24e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—CD44—hematologic cancer	4.19e-06	4.13e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—NQO1—hematologic cancer	4.19e-06	4.13e-05	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—AKT1—hematologic cancer	4.13e-06	4.07e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—CYCS—hematologic cancer	3.97e-06	3.9e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	3.94e-06	3.88e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	3.79e-06	3.73e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PIK3CG—hematologic cancer	3.62e-06	3.56e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—GSTP1—hematologic cancer	3.5e-06	3.44e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—CREBBP—hematologic cancer	3.35e-06	3.3e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—ABCB1—hematologic cancer	3.31e-06	3.26e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—NCOR1—hematologic cancer	3.21e-06	3.16e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—GSTM1—hematologic cancer	3.21e-06	3.16e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PIK3CD—hematologic cancer	3.18e-06	3.13e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—ALB—hematologic cancer	3.14e-06	3.09e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PIK3R1—hematologic cancer	3e-06	2.96e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—MTHFR—hematologic cancer	2.84e-06	2.79e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PIK3CB—hematologic cancer	2.77e-06	2.73e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PTEN—hematologic cancer	2.39e-06	2.36e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PIK3CG—hematologic cancer	2.38e-06	2.35e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—EP300—hematologic cancer	2.28e-06	2.25e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—CREBBP—hematologic cancer	2.21e-06	2.18e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PIK3CD—hematologic cancer	2.1e-06	2.06e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—ALB—hematologic cancer	2.07e-06	2.04e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PIK3R1—hematologic cancer	1.98e-06	1.95e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PIK3CB—hematologic cancer	1.83e-06	1.8e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PIK3CA—hematologic cancer	1.69e-06	1.66e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PTEN—hematologic cancer	1.58e-06	1.55e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—EP300—hematologic cancer	1.51e-06	1.48e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—AKT1—hematologic cancer	1.38e-06	1.36e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PIK3CA—hematologic cancer	1.11e-06	1.1e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—AKT1—hematologic cancer	9.1e-07	8.96e-06	CbGpPWpGaD
